美國食品藥物管理局高層人事變動
Major Leadership Changes at the US Food and Drug Administration
自2025年初至2026年4月間，美國食品藥物管理局（FDA）經歷了重大的組織變動。
Between early 2025 and April 2026, the U.S.
在「讓美國再次健康」（Make America Healthy Again）的議程下，馬丁·馬卡里博士（Dr.
Food and Drug Administration (FDA) experienced significant organizational shifts.
FDA的重心已轉向放寬監管，包括取消部分動物實驗要求並簡化審核流程。
The agency also saw 3,500 employees depart due to workforce reductions.
如「預先檢查」（PreCheck）計畫等新措施，旨在將藥物製造業移回國內。
The FDA's focus has shifted toward deregulation, including removing certain animal testing requirements and simplifying approval processes.
儘管有這些變革，該機構仍面臨不穩定與不可預測的艱難環境，影響了製藥與食品產業。
New initiatives like the "PreCheck" program aim to reshore drug manufacturing.
馬卡里局長已指出，要在維持機構文化同時管理這些過渡期確實存在困難。
Despite these changes, the agency faces a challenging climate of instability and unpredictability, impacting pharmaceutical and food industries.
